{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRecurrent+GBM+%28Phase+2%29",
    "query": {
      "condition": "Relapsed/Recurrent GBM (Phase 2)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 16,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRecurrent+GBM+%28Phase+2%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-19T19:15:10.773Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04238819",
      "title": "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed Solid Tumor",
        "Refractory Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Dinutuximab",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 47,
      "start_date": "2020-11-09",
      "completion_date": "2025-08-19",
      "has_results": true,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-09-19T19:15:10.773Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Oakland, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Santa Clara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04238819"
    },
    {
      "nct_id": "NCT01112527",
      "title": "PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "GBM",
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "PF-00299804",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2010-04",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2018-08-16",
      "last_synced_at": "2026-09-19T19:15:10.773Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Detroit, Michigan • Cleveland, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01112527"
    },
    {
      "nct_id": "NCT02800486",
      "title": "Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Anaplastic Astrocytoma",
        "Anaplastic Oligoastrocytoma",
        "Glioma",
        "Brain Neoplasm",
        "Brain Cancer",
        "Brain Tumor",
        "Brain Tumor, Recurrent",
        "Brain Neoplasm, Malignant"
      ],
      "interventions": [
        {
          "name": "Intra-arterial Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Intra-arterial Mannitol",
          "type": "DRUG"
        },
        {
          "name": "Hypofractionated re-irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2016-05",
      "completion_date": "2036-05",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-19T19:15:10.773Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02800486"
    },
    {
      "nct_id": "NCT02348255",
      "title": "NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Brain Glioblastoma",
        "Recurrent Adult Brain Neoplasm"
      ],
      "interventions": [
        {
          "name": "Electric Field Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-01",
      "completion_date": "2017-01",
      "has_results": false,
      "last_update_posted_date": "2018-01-09",
      "last_synced_at": "2026-09-19T19:15:10.773Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • Atlanta, Georgia",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02348255"
    },
    {
      "nct_id": "NCT00073944",
      "title": "BCX-1777 in Treating Patients With Refractory Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "forodesine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioCryst Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-05-30",
      "last_synced_at": "2026-09-19T19:15:10.773Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00073944"
    },
    {
      "nct_id": "NCT03175224",
      "title": "APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors",
        "Advanced Cancer",
        "Renal Cancer",
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "NSCLC",
        "Lung Cancer",
        "Brain Tumor",
        "Glioblastoma Multiforme",
        "EGFR Gene Mutation",
        "MET Amplification",
        "HGF",
        "Thyroid Cancer",
        "Pancreatic Cancer",
        "Colon Cancer",
        "MET Alteration",
        "MET Fusion",
        "Exon 14 Skipping"
      ],
      "interventions": [
        {
          "name": "APL-101 Oral Capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Apollomics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 497,
      "start_date": "2017-09-27",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-09-19T19:15:10.773Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03175224"
    },
    {
      "nct_id": "NCT00795665",
      "title": "Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "carmustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2008-06",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2020-05-12",
      "last_synced_at": "2026-09-19T19:15:10.773Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00795665"
    },
    {
      "nct_id": "NCT07416188",
      "title": "Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Glioblastoma",
        "Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype",
        "Relapsed Cancer",
        "Recurrent Tumor",
        "Glioblastoma Multiforme",
        "Recurring Glioblastoma",
        "Brain and Central Nervous System Tumors",
        "Glioma",
        "Glioblastomas",
        "Grade IV Astrocytoma",
        "GBM",
        "Recurrent Glioma (Glioblastoma Multiforme)",
        "High Grade Glioma",
        "Glioma, Malignant",
        "Brain Cancer"
      ],
      "interventions": [
        {
          "name": "LMP744",
          "type": "DRUG"
        },
        {
          "name": "Conventional Surgery or Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-07-15",
      "completion_date": "2032-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-09-19T19:15:10.773Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07416188"
    },
    {
      "nct_id": "NCT00704288",
      "title": "Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "XL184",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 222,
      "start_date": "2008-05",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2024-02-05",
      "last_synced_at": "2026-09-19T19:15:10.773Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00704288"
    },
    {
      "nct_id": "NCT01498328",
      "title": "A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Small Cell Glioblastoma",
        "Giant Cell Glioblastoma",
        "Gliosarcoma",
        "Glioblastoma With Oligodendroglial Component",
        "Recurrent Glioblastoma",
        "Relapsed Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Rindopepimut (CDX-110) with GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "KLH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2011-12",
      "completion_date": "2016-05-17",
      "has_results": false,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-09-19T19:15:10.773Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01498328"
    }
  ]
}